跳至主要内容
临床试验/EUCTR2012-002443-26-GB
EUCTR2012-002443-26-GB进行中(未招募)1 期

A phase II, multi-centre, open labelled randomised control trial to describe immune & transcriptomic responses to trivalent inactivated vaccine (TIV) & MF59 adjuvanted influenza vaccine (ATIV) in 14 -26 month healthy children - ADITEC FLU STUDY: Understanding the genetic basis for immune responses

niversity of Oxford0 个研究点目标入组 90 人开始时间: 2012年7月13日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • All of the following criteria need to be met to participate in the study:
  • 1.The investigator believes that the parents / legal authorised representative(s) (LARs) of the child can and will comply with requirements of the protocol (e.g. completion of diary cards, understanding of study procedure, consent process, availability at visits)
  • 2.Written informed consent obtained from parent / LAR (s) of the subject
  • 3.Age from 14 months to 26 months (from start of 14 months up to & excluding 27 months of age)
  • 4.Subject is healthy as determined by medical history and clinical examination
  • 5.Has received standard UK immunisation schedule
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • A participant cannot participate if any of the following criteria are met:
  • 1. The child is in care
  • 2. Use or planned use of any non-registered or investigational product in last 30 days
  • 3. Previous influenza vaccination
  • 4. Microbiologically proven influenza illness or treatment with antiviral medications
  • 5. Confirmed or suspected egg allergy or allergic reaction to previous vaccinations.
  • 6. Chronic serious medical conditions which may, in the opinion of the investigator, interfere with evaluation of study objectives e.g. Chronic lung disease, chronic liver/renal disease, chronic renal failure chronic heart disease, congenital genetic syndromes (e.g. Trisomy 21).
  • 7. Suspected or confirmed immunosuppressive or immunodeficiency conditions (including splenic dysfunction & HIV)
  • 8. Autoimmune conditions e.g. Type 1/2 diabetes mellitus, thyroid disease, juvenile idiopathic arthritis etc.
  • 9. Bleeding disorders

研究者

相似试验

进行中(未招募)
1 期
A study to compare the treatment of Vinblastine alone or in combination with Bevacizumab in children with progressive low grade glioma (LGG).
EUCTR2017-001982-26-GBThe Hospital for Sick Children150
进行中(未招募)
1 期
Study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first treatment in patients with advanced ALK-positive lung cancer
EUCTR2021-002567-22-FRIFCT110
招募中
2 期
A trial of sodium-copper-chlorophyllin given along with treatment of physicianâ??s choice versus treatment of physicianâ??s choice in asymptomatic or mildly symptomatic patients with Covid-19
CTRI/2021/02/030986IDRS Labs Private Limited
已完成
2 期
A clinical trial to study the effects of combination of two drugs, arterolane (RBx 11160) maleate and piperaquine phosphate given together and Coartem® in patients with acute uncomplicated Plasmodium falciparum malaria.
CTRI/2007/091/000031Ranbaxy Laboratories Ltd240
进行中(未招募)
不适用
APG101 in glioblastomaGlioblastoma Multiforme (first or second progression)MedDRA version: 14.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-013421-42-DEApogenix GmbH83